CClinicalTrials.gg
Status unknownNCT04809454I2 and thyroidUpdated Sep 22, 2021

Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt

An observational study in Thyroid Dysfunction, sponsored by Services Institute of Medical Sciences, Pakistan. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-09-22.

Sponsored by Services Institute of Medical Sciences, Pakistan · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Thyroxin a vital hormone for life lot of body functions depend on proper functioning on pituitary thyroid axis. it exists in two major forms Thyroxine (T4) and (T3) , each of them containing two iodine atoms on their inner (tyrosine) ring. Synthesis of reasonable quantities of thyroid hormones requires adequate iodine intake to allow sufficient thyroidal uptake. The World Health Organization (WHO) recommendation for daily intake of iodine is 150 μg for children ≥12 years and adults, and 250 μg for pregnant and lactating women. However as we know optimum amount of iodine is required for normal pituitary thyroid axis like wise excessive intake may cause over functioning of axis hence over production of hormone that can be manifested both clinically and biochemically.

This study is designed to observe the frequency of over hyperthyroidism in patients taking iodinated salt.

Read the detailed description

All patients presenting to endocrine clinic fulfilling inclusion and exclusion criteria will be recruited. They will be examined, their vitals including blood pressure pulse will be noted, thyroid clinical examination including eye signs and thyroid status will be done biochemical Thyroid profile (TSH, Free T3 \& Free T4) will be noted in predesigned proforma.

Statistical Analysis will be done ,after data is entered in Statistical Package for the Social Sciences (SPSS) version 25 .qualitative data will be presented as frequencies and percentages while quantitative data will be presented as mean medians and standard deviations.

02

Conditions studied

  • Thyroid Dysfunction

Browse trials for

Keywords

  • Thyroid
  • Iodine
03

In context

Hyperthyroidism

111 studies on the registry are indexed under Hyperthyroidism; 28 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 55 observational studies indexed under Hyperthyroidism.

Browse Hyperthyroidism studies →

Lead sponsor

Services Institute of Medical Sciences, Pakistan is the lead sponsor of 33 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All patients presenting with biochemical hyperthythyroidism and taking Iodinated salt with age range of 18-60 years

Inclusion criteria

  1. All patients presenting with biochemical hyperthyroidism
  2. Who are taking Iodinated salt.
  3. Treatment naïve patients
  4. Both genders included
  5. All patients who can give consent (18-60 years)

Exclusion criteria

Exclusion Criteria:

  1. Pregnant females 2) Lactating mothers

-

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Affect of Iodinated Salt on Thyroid Status

    Affect of Iodinated Salt on Thyroid Status

    Time frame: through study completion an average of 12 weeks

07

Study locations

1 site
  • Mehwish Iftikhar
    Lahore, Punjab 54000, Pakistan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04809454
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Responsible party
Mehwish Iftikhar (Principal Investigator, Services Institute of Medical Sciences, Pakistan) — Principal investigator
First posted
Mar 22, 2021
Start date
Oct 2021 (estimated)
Primary completion
Mar 2022 (estimated)
Completion
Mar 2022 (estimated)
Last update
Sep 22, 2021

Study contacts

Mehwish Iftikhar, FCPS Endocrinologyy
Contact
drmehwish19@gmail.com
923004291641
Amna Rizvi, FCPS Endocrinology
Contact
amnarizvi512@gmail.com
923009463345

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion